Components of the plasminogen activation system including urokinase (uPA), its inhibitor (PAI-1) and its cell surface receptor (uPAR) have been implicated in a wide variety of biological processes related to tissue homoeostasis. Firstly, the binding of uPA to uPAR favours extracellular proteolysis by enhancing cell surface plasminogen activation. Secondly, it promotes cell adhesion and signalling through binding of the provisional matrix protein vitronectin. We now report that uPA and plasmin induces a potent negative feedback on cell adhesion through specific cleavage of the RGD motif in vitronectin. Cleavage of vitronectin by uPA displays a remarkable receptor dependence and requires concomitant binding of both uPA and vitronectin to uPAR. Moreover, we show that PAI-1 counteracts the negative feedback and behaves as a proteolysis-triggered stabilizer of uPAR-mediated cell adhesion to vitronectin. These findings identify a novel and highly specific function for the plasminogen activation system in the regulation of cell adhesion to vitronectin. The cleavage of vitronectin by uPA and plasmin results in the release of N-terminal vitronectin fragments that can be detected in vivo, underscoring the potential physiological relevance of the process.
Introduction
The urokinase-type plasminogen activator (urokinase, uPA) and its cell surface receptor (uPAR) are core components of the plasminogen activation system in mammals and orchestrate different cellular processes, including extracellular proteolysis, cell adhesion, migration and proliferation [1, 2] . These functions of uPA and uPAR can mechanistically be categorized as either proteolytic or nonproteolytic, depending on the requirement for the catalytic activity of uPA in the process.
The proteolytic functions were the first to be characterized. Cells secrete urokinase as a single-chain zymogen (single-chain uPA, sc-uPA) that is converted into the active two-chain form (tc-uPA) by limited proteolysis. The binding of sc-uPA to uPAR, and plasminogen to one or more of the functionally related plasminogen receptors [3] , concentrates the two zymogens on the plasma membrane favouring their reciprocal activation [4] . This process endows cells with the focalized proteolytic activity believed to be responsible for the activity of the plasminogen activation system in tissue invasion. Various protease inhibitors control the proteolytic cascade; in particular, the primary physiological inhibitors of tc-uPA and plasmin are the two serpins plasminogen activator inhibitor 1 (PAI-1) and a-2-antiplasmin (a2AP), respectively. In addition, uPAR has been demonstrated to act as an endocytosis co-receptor for spent complexes between uPA and PAI-1 [5, 6] .
On the non-proteolytic side, overexpression of uPAR and/or treatment of uPAR-expressing cells with uPA induce signal transduction resulting in altered cell adhesion, migration, survival and proliferation. Lacking transmembrane and intracellular domains, uPAR itself is incompetent in signal transduction. A large number of independent studies has shown that the uPA/uPAR-induced signal is relayed into the cells through functional interactions with professional signalling receptors including several members of the integrin family of adhesion receptors, receptor tyrosine kinases (RTK) and G-protein-coupled receptors (GPCRs) (reviewed in [1] ). Over the latest years, it has emerged that the functional coupling between uPAR and integrins [7] [8] [9] , RTKs [10] and GPCRs [11] , occurs downstream of the direct binding of uPAR to the provisional extracellular matrix (ECM) protein vitronectin (VN). This suggests that the interaction between uPAR and the somatomedin B (SMB) domain of VN may act as the master switch for the signalling activity of uPA/ uPAR. Moreover, a recent in vivo study has documented the functional relevance of the uPAR/VN interaction for tumour growth [12] .
Although both the proteolytic and non-proteolytic functions of uPA/uPAR are well characterized, only little is known about how plasminogen activation affects the uPAR/VN interaction and how the uPAR/VN interaction impinges on plasminogen activation. Binding of sc-uPA to uPAR induces conformational changes in the receptor increasing its affinity for VN [13] , but it is not known what happens when uPA in the sc-uPA/uPAR/VN complex becomes activated. It has been shown that both tc-uPA and plasmin may cleave and inactivate uPAR [14, 15] , suggesting that receptor cleavage represents a negative feedback mechanism regulating both the proteolytic and the non-proteolytic functions of uPAR. Nevertheless, whether such feedback mechanisms are active and have functional consequences remains to be documented.
We here present direct mechanistic evidence that the proteolytic and non-proteolytic functions of uPAR are intimately interconnected through receptor-dependent proteolytic cleavage of the RGD motif in VN by uPA and plasmin. These findings provide novel conceptual insight into the biology of the plasminogen activation system, suggesting that a central function of the plasminogen activation system is to regulate cell adhesion and signalling through proteolytic inactivation of VN.
Results

Plasminogen activation exerts a negative feedback on cell adhesion to VN
To investigate the possible existence and mechanism of feedback loops between the function of uPAR in extracellular proteolysis and cell adhesion, we conducted time-lapse microscopy on HEK293 cells engineered to overexpress uPAR using the Flp-In system (293/uPAR [7] ). Cells were seeded on VN and exposed to consecutive additions of sc-uPA and plasminogen to trigger the plasminogen activation cascade (Fig 1A and B , and Movie EV1). When seeded on VN, 293/ uPAR cells displayed an adherent phenotype characterized by extensive lamellipodia formation that was further enhanced by sc-uPA addition. Treatment with plasminogen, however, rapidly reversed the pro-adhesive effect of sc-uPA as evidenced by lamellipodia retraction and the acquisition of rounded cell morphology, similarly to what has previously been reported for endothelial cells following plasminogen activation [16] . To quantitatively analyse the negative feedback, we utilized a real-time cell analysis (RTCA) instrument that allows for the continuous and non-invasive evaluation of the extent and quality of cell matrix interactions by impedance measurements [17] . The data obtained by RTCA analysis of 293/uPAR cells ( Fig 1C) closely paralleled the time-lapse microscopy recordings: after an initial adhesion phase the addition of sc-uPA caused a marked increase in cell adhesion that was rapidly reverted upon subsequent addition of plasminogen. The reduction in cell adhesion to VN induced by plasminogen activation was also observed using a plate-and-wash assay (Appendix Fig S1A) . The inhibitory effect of plasminogen activation on cell adhesion to VN was mediated by cell surface-associated plasmin and/or tc-uPA activity as the addition of a2AP, which inhibits free but not membrane bound plasmin [18] , had limited effect on the magnitude of the proteolytic feedback ( Fig 1C) . Mock-transfected HEK293 cells that do not express endogenous uPAR did not respond notably to treatments with sc-uPA and Plg (Appendix Fig S1B) . When 293/uPAR cells were seeded on FN, triggering the plasminogen activation cascade did not impair cell adhesion, but rather resulted in a delayed and transient increase (Fig EV1) . In contrast to VN, the transient increase in FN adhesion is mediated by the activity of free plasmin, as it was fully inhibited by a2AP.
These results evidence the existence of both positive and negative feedback loops between plasminogen activation and cell adhesion to VN and FN.
The catalytic activity of both uPA and plasmin contributes to the negative feedback
The process of cell surface plasminogen activation is a reciprocal zymogen activation cascade in which the zymogen sc-uPA is converted into active tc-uPA and the zymogen plasminogen into active plasmin, thus resulting in the concomitant generation of two distinct serine protease activities. To determine which of these activities is responsible for the negative feedback, we analysed the cellular response to the isolated proteases ( Fig 1D) . Both sc-uPA and tc-uPA stimulated VN adhesion to a similar extent and with similar kinetics, consistent with the fact that both contain the receptor binding growth factor-like domain (GFD) responsible for inducing uPAR binding to VN [13, 19] . However, after reaching peak levels, the adhesion of tc-uPA-treated cells started to decline as compared to cells treated with sc-uPA, demonstrating that the catalytic activity of uPA contributes directly to the feedback. Catalytically active low molecular weight uPA (LMW-uPA), lacking the GFD domain, failed to induce the feedback demonstrating the requirement for uPA binding to uPAR (Appendix Fig S1C) . Furthermore, control experiments using the plasmin inhibitor aprotinin, tc-uPA purified from human urine and catalytically inactive uPA variant (uPA S356A ) excluded the possibility that the plasmin used for activation of recombinant sc-uPA was responsible for the observed negative feedback (Appendix Fig S1C) .
The feedback induced by tc-uPA was not as steep as that observed with a combination of sc-uPA and plasminogen (see Fig 1B) , indicating that the catalytic activity of uPA is not sufficient to obtain the full magnitude of the feedback. Consistently, the addition of plasminogen to tc-uPA-treated cells further accelerated the feedback. To evaluate the direct contribution of plasmin, we first treated cells with the GFD domain of uPA to mimic the pro-adhesive effect of ligand occupancy and then challenged the cells with active plasmin. Under these conditions, the treatment with plasmin caused a rapid decrease in cell adhesion showing that the proteolytic activity of plasmin also contributes directly.
The negative feedback is partially acting through uPAR cleavage
It has been recognized for a long time that the linker region connecting domain 1 (D1) and domains 2 and 3 (D2D3) of uPAR is highly susceptible to proteolysis by various proteases including uPA and plasmin [20] . Since the binding site for VN in uPAR involves determinants in both D1 and D2D3 [7, 13] , cleavage of the linker region connecting these domains could possibly account for the negative feedback. To address this possibility, we generated HEK293 cells expressing a uPAR variant (uPAR R83/89A ) in which the reported uPA and plasmin cleavage sites ( 83 R↓A and 89 R↓S) have been disrupted by alanine substitutions. Analysis by flow cytometry confirmed that the different receptor variants were equally expressed on the cell surface (Appendix Fig S1D) and induced largely comparable cell adhesion to VN (Appendix Fig S1E) . In cells expressing the uPAR R83/89A receptor (Fig 1E) , the onset of the negative feedback induced by tc-uPA was markedly delayed as compared to cells expressing uPAR WT (Fig 1D) , indicating that uPAR cleavage indeed contributes to the feedback. Notably, however, the impairment of receptor cleavage did not fully phenocopy the effect of treatment with catalytically inactive sc-uPA showing that other proteolytic events must be involved. In support of this, the treatment of 293/ uPAR R83/89A cells with GFD followed by plasmin also resulted in a pronounced reduction in VN adhesion. Western blotting analysis using domain-specific antibodies confirmed that the treatment with tc-uPA, as well as sc-uPA plus plasminogen, resulted in efficient cleavage of uPAR WT , but not uPAR R83/89A (Fig 1F) . Importantly, despite its pronounced effect on cell adhesion, plasmin treatment did not result in marked uPAR cleavage. These data thus demonstrate that cleavage of uPAR is only partially responsible for the negative feedback and that other functionally relevant uPA/plasmin substrates must be involved in the process. A representative experiment is shown. E The cleavage of uPAR partially contributes to the negative feedback. [51] . R2 binds an epitope in D3 of uPAR and recognizes the full-length receptor (uPAR) as well as the truncated form lacking D1 (D2D3). R3 binds an epitope in D1 and only recognizes full-length uPAR. The blot is from a representative experiment and the mobility of molecular weight standards is shown. 
Plasmin cleaves the RGD motif in VN
Plasmin cleaves purified VN at multiple locations [21, 22] , and the treatment of VN-coated surfaces with plasmin has been shown to attenuate subsequent a v b 5 -dependent adhesion of keratinocytes [23] . Consistent with these observations, we found that pre-treatment of VN-coated surfaces with plasmin, but not with tc-uPA, resulted in a dose-dependent reduction of subsequent cell adhesion (Fig 2A) . The inhibitory effect was not specific for uPAR-mediated cell adhesion as the integrin-mediated adhesion of HeLa cells was also impaired (Fig 2A) . The inhibitory effect of plasmin was, however, specific for VN as identical treatments of FN failed to modulate subsequent cell adhesion (Fig 2B) . Fig S1F) . To identify these novel cleavage sites, we treated intact VN with plasmin and analysed the reactions by MALDI-TOF mass spectrometry (Fig 2C) . The molecular weight of the main peak observed in the resulting spectra closely matched that of an N-terminal VN fragment (VN(1-45)) generated by cleavage within the RGD motif ( 45 R↓GD). A peak with the same mass, but lower intensity, was also observed in spectra of non-treated A B C Figure 2 . Plasmin cleaves VN in the RGD motif.
A Pre-treatment of VN with plasmin, but not uPA, inhibits subsequent cell adhesion mediated by uPAR and integrins. E-plates wells coated with VN were incubated with a dilution curve of plasmin or tc-uPA for 1 h at 37°C prior to cell seeding. After washing, 293/uPAR WT or HeLa cells were seeded and their adhesion was followed by RTCA. The cell indexes recorded 1 h after seeding are shown. Data are reported as percentage of the cell index measured in non-pre-treated wells and represent the mean AE SD of three independent experiments. B Pre-treatment of FN with plasmin or tc-uPA does not affect subsequent cell adhesion. RTCA experiments were performed as described for (A), but with FN-coated wells. Data are reported as percentage of the cell index measured in non-pre-treated wells and represent the mean AE SD of three independent experiments. C Plasmin cleaves VN at the 45 RG peptide bond. Urea-purified VN was incubated with plasmin (substrate/enzyme ratio: 10:1 w/w) for 2 h at 37°C and the reactions were analysed by MALDI-TOF mass spectrometry. -Fc) containing an alanine substitution of 45 R. The treatment of this VN variant rather resulted in a peak corresponding to a molecular species generated by cleavage after a lysine ( 78 K) located in the Fc tag (Fig EV2D) . Taken together, these data conclusively identify the RGD motif as a cleavage site for plasmin in VN.
Cleavage of the RGD motif in VN is responsible for the negative feedback between plasminogen activation and cell adhesion
To determine whether the identified target site is also functionally responsible for the feedback between the plasminogen activation cascade and cell adhesion on VN, we performed RTCA experiments using 293/uPAR R83/89A cells seeded on VN and different VN variants in which cleavage has been prevented by alanine substitution of 45 R in the RGD motif (see cartoon in Fig 3A) .
Since the 45 R?A substitution employed to prevent cleavage also results in impaired integrin binding, we generated a second control variant carrying a G? A) gave rise to a negative feedback significantly more potent than that of the wild-type RGD motif (Fig 3C) . This finding may be explained in at least two ways: firstly, the RAD sequence may be a better substrate for uPA than the RGD sequence; secondly, integrin binding to the RGD motif may protect it from proteolysis. In vitro cleavage experiments using purified components indicated that the 45 RA peptide bond is indeed more susceptible to proteolytic cleavage than the wild-type 45 RG sequence (Appendix Fig S2A and B) . Considering the small size of the RGD motif, it is also plausible that integrin occupancy may prevent proteases from assessing the cleavage site by steric hindrance, but we did not test this experimentally. When cells were treated with a combination of sc-uPA, plasminogen and a2AP (Fig 3D) , the (Fig EV3A and B) . This analysis revealed that cleavage at both locations contributes to the negative feedback and that these sites are the only important ones in uPAR as alanine substitution of both completely abolished the negative feedback.
The data thus demonstrate that the proteolytic feedback between plasminogen activation and cell adhesion to VN is functionally mediated by cleavage of both VN and uPAR and catalysed by both tc-uPA and plasmin. In the process, the cleavage of VN appears to be relatively more important than cleavage of uPAR. The cleavage site in VN responsible for the negative feedback is 45 R↓G in the RGD motif even if other functionally relevant plasmin cleavage sites may exist.
uPAR accelerates the cleavage of matrix VN by uPA and plasmin
Proteolytic cleavage of matrix bound VN in the RGD motif is expected to result in the release of an N-terminal VN fragment (i.e. the SMB domain) from the connecting region and C-terminal hemopexin-like domains, which mediate the binding of VN to other ECM components [24] . To quantify this release, we treated immobilized VN with different forms of uPA and plasminogen in the absence or presence of 293/uPAR cells and measured the levels of SMB-containing VN fragments released to the conditioned medium ( Fig 4A) . In the absence of cells, only the treatment with plasmin was found to release VN fragments, consistent with the pre-treatment experiments (Fig 2A) , whereas the presence of 293/ uPAR cells resulted in the release of VN fragments also by tc-uPA and the combination of sc-uPA, plasminogen and a2AP. The plasmin inhibitor aprotinin did not inhibit the release mediated by uPA excluding the possibility that trace amounts of plasmin in the uPA preparation were responsible for the proteolysis (Appendix Fig S3A) . The release of VN fragments was caused by cleavage within the RGD motif as it was impaired by the R45A substitution (Appendix Fig S3B) . Furthermore, the release mediated by tc-uPA requires the following: (i) uPAR expression, as mock-transfected cells did not induce release; (ii) uPA binding to uPAR, as the release was impaired by the GFD domain of uPA; (iii) uPAR binding to VN, as cells expressing a VN binding-deficient uPAR mutant (uPAR
R91A
) failed to promote the release and because an antibody (8B12) binding to the VN epitope in uPAR [25] also prevented release ( Fig 4C) . The mode of action of the different compounds/ mutations utilized is depicted in Fig 4B . Similar results were observed for the treatment with sc-uPA, plasminogen and a2AP (Fig EV4) , even if the inhibition by GFD and the impairment by the uPAR 91 R?A substitution in this case were only partial. The more likely explanation for this difference is that the cleavage of matrix VN by cell surface plasmin is less dependent upon the direct uPAR/VN interaction and that the concentration of GFD used for competition was insufficient to block plasminogen activation.
These data show that VN fragments containing the SMB domain are released from matrix VN upon plasminogen activation in a highly specific process that is accelerated by the binding of both uPA and VN to uPAR. The observation that direct binding of both uPA and VN to the receptor is required for optimal cleavage by uPA suggests that uPAR facilitates the reaction by a mechanism of substrate presentation in which the receptor coordinates the enzyme (uPA) and its substrate (VN) favouring the contact between the catalytic triad of uPA and the RGD motif in VN. To test this hypothesis, we incubated VNcoated wells with a fixed concentration of uPA together with increasing concentrations of an Fc-tagged soluble uPAR and measured the concomitant release of VN fragments (Fig 4D) . Consistent with a mechanism of substrate presentation, the addition of soluble uPAR indeed resulted in a dose-dependent release of SMB-containing VN fragments. The release required catalytically active tc-uPA as no release was observed with sc-uPA, and VN binding to uPAR as no significant release was induced by a VN bindingdeficient variant of uPAR. The levels of uPAR binding to VN (Fig 4E) and the amounts of released SMB were highly correlated (Pearson's r = 0.94, P < 0.0001, Fig 4F) . Although suPAR accelerates the cleavage of VN by uPA, the cleavage efficiency remains low The R45A mutation in VN strongly impairs tc-uPA-mediated negative feedback. 293/uPAR R83/89A cells were seeded on VN R45A or VN G46A and treated with 10 nM scuPA or tc-uPA at the indicated time point (stippled vertical line). A representative RTCA experiment is shown. C, D Cleavage of VN in the RGD motif is responsible for the negative feedback of plasminogen activation on cell adhesion to VN. 293/uPAR R83/89A cells were seeded on different VN variants and treated with 10 nM sc-uPA, 10 nM tc-uPA (C) or with a combination of 10 nM sc-uPA, 30 nM Plg and 100 nM a2AP (D). To merge independent experiments, the cell index measured after 6 h of treatment is shown in % of the one measured for cells seeded on the same substrate, but treated with sc-uPA, as depicted in (B). Dots are data from independent experiments and means AE SD are shown. The significance levels were evaluated using Student's t-test (two-tailed). *P < 0.05, **P < 0.01 and ***P < 0.001.
Valentina De Lorenzi et al Cleavage of the RGD motif regulates cell adhesion EMBO reports compared to the same reaction catalysed by Pli (Appendix Fig S4) . To confirm these data by an independent method and to conclusively identify the cleavage site for uPA in VN, MALDI-TOF analysis was conducted on VN incubated with tc-uPA in the presence or absence of uPAR. Both in the absence (Fig EV5A) and in the presence of the receptor (Fig EV5B) , a molecular species corresponding to VN(1-45) was observed, but the intensity of this peak was consistently and significantly higher in reactions containing also uPAR ( Fig EV5C) . The data thus demonstrate that uPAR accelerates the cleavage of VN catalysed by uPA and that the predominant cleavage position is 45 R↓G, consistent with the functional data.
PAI-1 counteracts the negative feedback and behaves as a proteolysis-dependent agonist of uPAR-mediated cell adhesion on VN A prediction of the above findings is that specific inhibitors of uPA and Pli may stabilize cell adhesion in conditions where the plasminogen activation system is active. In particular, PAI-1 is expected to be of central importance in this respect as it is both an irreversible inhibitor of uPA as well as a potent competitive antagonist of the uPAR/VN interaction. Complex formation between uPA and PAI-1 results in the loss of two activities that suppress cell adhesion, that is the competitive binding of PAI-1 to VN [26] and the A Plasminogen activation results in the generation of N-terminal VN fragments containing the SMB domain. 293/uPAR cells were seeded on VN and treated with 10 nM sc-uPA and tc-uPA, 30 nM Plg and Pli, and 100 nM a2AP for 2 h at 37°C. The supernatants were harvested and the level of SMB-containing VN fragments was measured by immunoassay (see Materials and Methods section). Values represent the mean AE SD of at least 3 independent experiments. The statistical significance was probed using Student's t-test (two-tailed). nd: not determined, ns: P > 0.05, ***P < 0.001 and ****P < 0.0001. B Cartoon illustrating the mechanism of action of the different compounds/mutation used in (C). The monoclonal antibody 8B12 is a competitive inhibitor of the interaction between uPAR and VN, having a binding site overlapping with that of VN [25] . The Arg91 residue in uPAR is part of the VN binding epitope in uPAR. The GFD domain of uPA is a competitive antagonist of uPA binding to uPAR. ***P < 0.001 and ****P < 0.0001. C The generation of soluble VN fragments containing the SMB domain requires binding of both uPA and VN to uPAR. Cells were plated on VN and treated with 10 nM tc-uPA. Where indicated, a 30 min pre-incubation with 300 nM GFD or 30 lg/ml 8B12 was performed. Conditioned media were analysed as described in (A). Values represent the mean AE SD. The statistical significance was probed using Student's t-test (two-tailed). 
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proteolytic degradation of VN and uPAR described here. We therefore reasoned that the uPA•PAI-1 complex, in contrast to its molecular precursors, would be a stable agonist of cell adhesion to VN as: (i) it is proteolytically inactive and consequently unable to cleave uPAR and VN, (ii) does not bind to VN and therefore cannot compete with uPAR binding, (iii) maintains high-affinity binding to uPAR [27] and promotes receptor binding to VN [19] . To address this hypothesis, we first tested the biological activity of PAI-1, a combination of PAI-1 and tc-uPA (1:1) as well as purified uPA•PAI-1 complex in modulating uPAR-mediated cell adhesion to VN. Consistent with its high-affinity binding to the SMB domain, PAI-1, but not a mutant PAI-1 deficient in VN binding [28] , acted as a potent antagonist of uPAR-mediated cell adhesion to VN (Fig 5A and  Appendix Fig S5A) . On the contrary, the combination of tc-uPA and PAI-1, as well as the purified uPA•PAI-1 complex, displayed strong agonistic activity. Morphological analysis of cells subjected to the different treatments (Fig 5B) evidenced that treatment with PAI-1 induced cell rounding, while treatment with uPA•PAI-1 complex induced cell spreading. The quantification of these observations is presented in Appendix Fig S5B. Since the strength of cell adhesion and extent of spreading are major determinants of cell migration, we also evaluated the biological effect of the treatments on the 2D migration velocity (Fig 5C and Although not evident in the experiment presented in Fig 5A, also the anti-adhesive activity of PAI-1 was frequently found to be transient (Appendix Fig S5A) . Together, these data suggest that the reaction of PAI-1 with tcuPA promotes cell adhesion to VN by dual mechanisms. Firstly, inactivation of the catalytic activity of tc-uPA by PAI-1 halts VN and uPAR cleavage and therefore also the negative proteolytic feedback between plasminogen activation and cell adhesion. Secondly, complex formation between uPA and PAI-1 impairs the VN binding activity of PAI-1 and therefore its antagonistic effect on cell adhesion. As PAI-1 reacts extremely slowly with sc-uPA [30] , the interaction between uPA and PAI-1 is triggered by zymogen activation of sc-uPA, possibly by cell surface-generated plasmin. To verify the occurrence of this complex series of reactions, we seeded 293/uPAR cells on VN and treated them with a combination of sc-uPA and PAI-1 ( Fig 5D) . As expected from the agonistic activity of sc-uPA and the antagonistic activity of PAI-1 on cell adhesion, the effect of the combined treatment was intermediate to the effect of the individual treatments. Remarkably, the subsequent treatment with Plg resulted in a potent induction of cell adhesion that was not observed in the absence of PAI-1.
These data clearly identify a central role for PAI-1 in the process. In the absence of proteolysis, PAI-1 acts as a suppressor of cell adhesion through its high-affinity binding to VN. In conditions of plasminogen activation, the activity of PAI-1 is reverted into pro-adhesive as it is released from VN, protects VN and uPAR from proteolysis by inhibition of tc-uPA (Appendix Fig S5C) and enforces the uPAR/VN interaction.
VN cleavage correlates with the expression of uPA in cancer cell lines
To probe the importance of the plasminogen activation system in matrix VN cleavage as well as to determine the relative importance of the individual plasminogen activation system components in the process, we extended the analysis to the 38 epithelial cell lines of the NCI-60 panel [31] representing cancers of the breast, colon, lung, ovary, prostate and kidney. The different cell lines were seeded in VN-coated wells and incubated in the absence or presence of exogenous Plg and a2AP. In the absence of Plg and a2AP, 23 (61%) of the cell lines released levels of SMB above background (no cells) and this number increased to 35 (92%) in the presence of Plg and a2AP (Fig 6A) . MALDI-TOF analysis of conditioned medium from selected cell lines (HOP92 and OVCAR_5) evidenced the celldependent generation of a VN(1-45) fragment corresponding to cleavage within the RGD motif (Appendix Fig S6) as observed for purified tc-uPA and plasmin. Across all cell lines, a highly significant sevenfold increase in released SMB was measured in the presence of Plg and a2AP and this increase was almost entirely cell dependent as the treatment with Plg and a2AP in the absence of cells did not result in any significant increase. Comparing the release measured for the different cell lines in the absence and in the presence of Plg and a2AP did not evidence any strong associations between the aetiology of the cell lines and the levels of VN fragments released (Appendix Fig S7A and B) . A wealth of baseline "omics" data is available for the NCI-60 panel of cell lines through the CellMiner web tool [32] and we next queried this information using the concentrations of VN fragments released by the different cell lines. In this analysis, the transcript encoding uPA (PLAU) was found to correlate strongly with SMB release (r = 0.569, P = 0.002). The absolute strength of this correlation is underscored by the fact that the PLAU transcript ranks 3 out of the 25,722 transcripts in the database (Fig 6B and Dataset EV1 ). Transcripts encoding other core components of the plasminogen activation system, including uPAR (PLAUR), tPA (PLAT), PAI-1 (SERPINE1), PAI-2 (SERPINB2) and Plg-R KT (PLGRKT) did not correlate significantly with SMB release (Dataset EV1), suggesting that the expression level of uPA represents the rate-limiting step of the process.
These data demonstrate that most cancer cell lines are harnessed to degrade matrix VN, the process is strongly potentiated by exogenous Plg and the expression level of uPA is rate-limiting.
Plasminogen activation attenuates the adhesion of cancer cell lines to VN
The SMB release data document that cancer cells employ cell surface plasminogen activation to process matrix VN, but they do not demonstrate whether this proteolytic event has any functional consequences for cell adhesion. To address this point directly, we conducted RTCA experiments for the same 38 cell lines seeded on VN and incubated with Plg and a2AP or vehicle control (Fig 6C) . The basal cell adhesion to VN was found to correlate with the expression levels of the canonical VN receptor a V b 3 integrin, while, among the components of the plasminogen activation system, only PAI-1 expression levels displayed a weak but significant correlation (Fig 6D and Dataset EV2 ). The treatment with Plg and a2AP resulted in a highly significant (P = 0.0005) 17% reduction in average cell adhesion measured 16 h after treatment (Fig 6C) . Importantly, the magnitude of the reduction recorded for the individual cell lines (Appendix Fig S7C) was strongly correlated with the concentrations of SMB released by the same cell lines (Fig 6E) . As for SMB release, also the reduction in cell adhesion correlated (r = 0.47, P = 0.003) with PLAU expression levels (Fig 6D and  Dataset EV3 ). Despite the strong correlation between uPA expression levels and reduction in cell adhesion, the exogenous addition of tc-uPA to selected cell lines plated on VN did not result in a decrease in cell adhesion (Appendix Fig S8) . This may indicate that the proteolytic activity of plasmin has a predominant role in the process or that endogenously expressed, but inactive, sc-uPA competes for uPAR binding with the exogenously added enzyme.
The identified cleavage site in VN and the highly significant correlation between the reduction in cell adhesion and the release of VN fragments evidence that proteolysis of matrix VN by components of the plasminogen activation system indeed regulates cell adhesion.
Identification of N-terminal VN fragments in vivo
Cleavage of VN in the RGD motif generates small N-terminal SMBcontaining fragments that are released from the extracellular matrix to the surrounding fluid phase. To investigate whether such fragments are also generated in vivo, we analysed two liquid biopsies (ascites fluid) of ovarian cancer patients by MALDI-TOF (Fig 7A-C) . The resulting spectra documented the presence of the VN-derived peptides VN(1-45) and VN . The first of these peptides is identical to the fragment generated by uPA or plasmin cleavage described above, while the second is likely to represent a processed form generated by the removal of the C-terminal arginine residue by one or more carboxypeptidases well known to be abundant in biological fluids. Also in urine N-terminal VN fragments could be readily identified. The VN(1-45) fragment was not detected, but shorter forms of VN(1-44), VN(1-42) and VN(1-41) were abundant (Fig 7D) . These data demonstrate that VN fragments compatible with a cleavage by uPA/plasmin in the RGD motif can indeed be found in vivo.
Discussion
Since the discovery of the importance of the RGD sequence for the adhesive properties of FN more than three decades ago [33] , the central importance of this sequence motif has been extensively substantiated for a variety of ECM proteins [34] . The provisional ECM component VN contains a single RGD motif that is both required and sufficient for the cell adhesive activity of the protein [35] . We here demonstrate that the adhesive properties of VN are intimately regulated by the proteases of the plasminogen activation system, which inactivate the protein through specific cleavage of the RGD motif.
The serine protease uPA is endowed with very narrow substrate specificity, and only few substrates have been extensively A The SMB domain is released by a wide variety of cancer cell lines. The cancer cell lines of epithelial origin belonging to the NCI-60 panel (n = 38) were seeded on VN in the absence or presence of 30 nM Plg and 100 nM a2AP. The supernatants were harvested after 16 h and the level of SMB-containing VN fragments was measured by immunoassay. Dots represent the concentration measured for the individual cell lines or the value obtained analysing control wells (no cells) from 10 independent experiments. Means AE SD are shown. The statistical significance was probed using paired Student's t-test (two-tailed). *P < 0.05 and ****P < 0.0001. B PLAU mRNA expression levels correlate with the SMB release. The levels of SMB released in the presence of Plg and a2AP were used as a query pattern and correlated with the expression levels of about 26,000 genes across the NCI-60 panel, using the CellMiner web tool [32] . The table shows A-D Human ascites and urine samples were immunoprecipitated with HU3-conjugated beads, and eluted material was analysed by MALDI-TOF mass spectrometry.
Representative spectra are shown.
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i.e. plasminogen, PAI-1 and uPAR). We here identify VN as a novel direct substrate for uPA and demonstrate that the cleavage reaction is enhanced by a unique mechanism of substrate presentation in which uPAR directly binds and constructively coordinates both the enzyme (uPA) and the substrate (VN) as illustrated in the cartoon in Fig 8. Although the ternary structure of the scuPA/uPAR/VN complex still has to be determined, experiments employing small-angle X-ray scattering have demonstrated that activation of sc-uPA to tc-uPA is associated with increased interdomain flexibility [36] , possibly permitting an optimal positioning of the catalytic domain relative to the RGD motif in VN. It is well described that cell surface uPAR accelerates plasminogen activation by uPA [4] , but in this case, the receptor does so by concentrating the enzyme to the cell surface where also the substrate (plasminogen) binds. In fact, in contrast to the cleavage of VN presented here, purified soluble uPAR does not accelerate plasminogen activation by uPA [4] . Similarly, the cleavage of cell surface uPAR by uPA requires binding of the protease to the receptor [14] , while the much less efficient cleavage in solution is entirely independent of receptor binding [20] . We therefore believe that VN represents the first substrate for uPA to display a marked uPAR dependence. Although uPA directly cleaves the RGD motif in VN, the process is greatly accelerated when the plasminogen activation cascade is also triggered (i.e. in the presence of plasminogen). Indeed, we show that also cell surface-associated and free plasmin cleaves the RGD motif in VN and that the reaction is even more efficient than the catalysis by uPA. Although we have here sought to dissect the relative contribution of uPA and plasmin to VN cleavage, it is important to note that these two proteases are likely to act together physiologically as they are also responsible for each other activation.
Plasmin has previously been reported to cleave VN at multiple locations in the central and C-terminal regions of the protein [21, 22] . However, we have here demonstrated that the functional proteolytic feedback between plasminogen activation and cell adhesion can be recapitulated using a short recombinant form of VN that contains none of the previously reported target sites, suggesting that cleavage of the RGD motif is the functionally relevant event. Cleavage of VN within or close to the RGD motif has also been reported for the serine protease granzyme B [37] and the cancer-related serine protease tissue kallikrein 14 [38] .
The overlapping binding sites for uPAR and PAI-1 in the small N-terminal SMB domain in VN, immediately proximal to the RGDmotif, strongly suggest the existence of relevant functional interplay between the components of the plasminogen activation system and cell adhesion. Consistently, such crosstalk has been documented. Firstly, PAI-1 has been shown to act as an antagonist of cell adhesion to VN through its competitive inhibition of adhesion receptors binding to the RGD motif [39] . Secondly, both uPAR and uPA have been characterized as agonist of cell adhesion to VN, with uPAR acting as a bona fide VN adhesion receptor [40] and uPA as a soluble factor increasing the affinity and avidity of uPAR for VN [13, 41] . The findings presented here, starting from the discovery of cleavage of the RGD motif by uPA and plasmin, clearly suggest a novel and radically different view on the function of the plasminogen activation system components in the regulation of cell adhesion to VN. Firstly, our data document that uPA and uPAR may act as negative regulators of cell adhesion by targeting the proteolytic activity of the plasminogen activation system towards the RGD motif. Secondly, the data show that PAI-1 may act as a positive regulator of cell adhesion by silencing the proteolytic activity of the plasminogen activation system and through stabilization of the uPAR/VN interaction. Do uPA and uPAR promote or reduce cell adhesion to VN? Extensive evidence demonstrates that uPAR interacts directly with VN through a mechanism that is stimulated by concomitant ligand occupation by uPA or its derivatives containing the N-terminal GFD domain including sc-uPA, tc-uPA [13] and the uPA•PAI-1 complex [19] . When overexpressed by transfection, it is equally well demonstrated that the uPAR/VN interaction leads to increased cell adhesion, spreading and migration by mechanisms that have been carefully investigated by others and us and have lead to a significantly better understanding of the mechanisms by which non-integrin adhesion receptors signal [7] [8] [9] 42] . Nevertheless, little is known/published about the contribution of uPAR and uPA to cell adhesion when expressed at pathophysiological levels.
Our analysis of the adhesive properties of the 38 epithelial cell lines of the NCI-60 panel demonstrates that the mRNA expression levels of both uPA and uPAR display non-significant correlation with baseline cell adhesion to VN (r = 0.10; P > 0.5), suggesting that neither of these proteins contributes significantly to baseline cell adhesion to VN in vitro. Across the same cell lines, the expression levels of mRNAs encoding proteins well established to be involved in cell adhesion to VN, such as the a and b chains of the canonical VN integrin (ITGAV/ITGB3), are strongly correlated with cell adhesion (r = 0.5 and 0.6; P < 0.001), confirming the power of the analysis. Importantly, however, when analysing the impact of plasminogen activation on cell adhesion to VN, the expression level of uPA is among the absolute strongest correlates with reduced cell adhesion.
Taken together, these findings thus suggest that the more important function of uPA and uPAR, at least in vitro, is to enhance the proteolytic turnover of VN and consequently to limit cell adhesion on this substrate.
Is PAI-1 an agonist or an antagonist of cell adhesion to VN? To act as an antagonist of cell adhesion, PAI-1 needs to saturate the extracellular matrix VN and this activity is therefore expected in conditions of high PAI-1 expression. Quantitative analysis of breast carcinoma tissue protein extracts has documented a 10-to 1,000-fold excess of VN over uPA and PAI-1 (both present at comparable levels) [43] , suggesting that the anti-adhesive activity of PAI-1 is globally disfavoured. The concentrations of PAI-1 may locally be sufficiently high to impact cell adhesion, but even under these conditions, the inhibitory activity of PAI-1 is limited by its latency conversion and complex formation with tc-uPA, both of which lead to the dissociation of the molecule from VN. We here document that complex formation between PAI-1 and uPA may enhance cell adhesion to VN by at least three different mechanisms. Firstly, the reaction of PAI-1 with uPA halts plasminogen activation and therefore the proteolytic inactivation of VN. Secondly, we show that the uPA•PAI-1 complex is a strong and irreversible agonist of uPAR binding to VN. Thirdly, complex formation with uPA results in the release of PAI-1 from matrix VN, liberating binding sites for adhesion receptors. It is difficult to estimate which of these mechanisms is dominant, in particular in vivo, but importantly, they are all potentially active at concentrations of PAI-1 equal to or even below those of tc-uPA. Notably, the three mechanisms by which PAI-1 may promote cell adhesion are only operational under conditions in which active tc-uPA is generated and PAI-1 therefore behaves a proteolysis-triggered promoter of cell adhesion. Correlation analysis employing the NCI-60 panel of cell lines demonstrates a weak, but significant, positive correlation between PAI-1 mRNA levels and cell adhesion to VN, indicating that the pro-adhesive properties of PAI-1 are likely to be the most important at least in vitro.
The data presented here may have important physiological implications. It is well documented that uPAR accelerates plasminogen activation and localizes the generated proteases on the cell surface and we now demonstrate that the provisional matrix protein VN is a highly specific substrate for these proteolytic activities. While plasmin is crucial for fibrin surveillance in vivo [44] , the only process that has been well documented to require the binding of uPA to uPAR in vivo is the suppression of inflammation secondary to fibrin deposition [45] . We propose that while plasmin is responsible for the resolution of fibrin deposits in the provisional matrix, the main function of uPA/uPAR may be to bind and promote the focused degradation of VN. Also in the context of cancer, our findings provide novel mechanistic insight that might explain the peculiar prognostic values of uPA and PAI-1 in certain types of tumours. The well-documented observation that high levels of both uPA (an enzyme) and PAI-1 (its specific inhibitor) correlate with poor prognosis is known as the PAI-1 paradox [46] . We here provide mechanistic evidence demonstrating that together these molecules, even if endowed with opposite biochemical activities, cooperate in driving the same biological process (cell adhesion to VN). This conclusion would support a scenario in which high expression of the components of the plasminogen activation system, when expressed together, might act in concert to promote cancer progression through increased fibrosis, cell adhesion and tissue stiffening, rather than through excessive ECM degradation and turnover.
We show that small N-terminal fragments of VN consistent with processing of the RGD motif are present in liquid biopsies of cancer patients as well as in the urine of healthy individuals. These data show that proteolytic processing of VN indeed occurs in vivo providing support for a physiological role of this cleavage. Although further studies are required to determine to which extent these fragments are 
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Materials and Methods
Material
Human urea-purified VN was obtained from Promega and human FN from Trimital. Human Glu Plg, human Pli and human a2AP were purchased from Molecular Innovations. Aprotinin was purchased from SIGMA. Anti-uPAR monoclonal antibody R2 and R3 are a kind gift of Dr. Gunilla Hoyer-Hansen (Finsen Laboratory, Denmark). GFD was kindly provided by Dr. Steve Rosenberg. sc-uPA was kindly provided by Dr. Jack Henkin (Abbott Laboratories, Abbott Park, IL).
To obtain active tc-uPA either WT or S356A, the single-chain form was incubated with Pli (100:1, w:w ratio) for 30 min at 37°C and Pli was subsequently inactivated with an excess of a2AP. Human tcuPA prepared from human urine and human recombinant LMW-uPA were purchased from Molecular Innovations.
Expression and purification of recombinant proteins
The expression vectors described in the Appendix Supplementary Methods were transfected into CHO Flip-In cells (Invitrogen Corp.) and the recombinant proteins expressed under serum-free conditions as previously described [7] . Recombinant Fc-tagged proteins were purified from the conditioned media by standard Protein A affinity chromatography and dialysed extensively against PBS. Histagged proteins were purified by immobilized metal-affinity chromatography and dialysed extensively against PBS. Human PAI-1 WT and PAI-1 R103A/M112A/Q125A
, extended at the N-terminus with a His6 tag and recognition motif for heart muscle kinase, were expressed in Escherichia coli and purified by nickel affinity chromatography and size-exclusion chromatography as previously described [47] . A fully active fraction was generated by hydrophobic chromatography using phenyl-Sepharose and an ammonium sulphate gradient [48] . The N-terminal extension did not affect the specific inhibitory activity of PAI-1, its second-order rate constant for reaction with uPA, its VN binding or its rate of latency transition [47] . The uPA•PAI-1 complex was prepared by allowing the reaction to proceed for 3 h at 37°C. Purification of the complex was achieved by affinity chromatography using, in order, Sepharose-bound anti-PAI-1 Mab-2 and anti-uPA Mab-6 (monoclonal anti-uPA antibody from hybridoma clone 6), essentially as described previously [49] .
Generation of monoclonal anti-VN antibodies
C57Bl/6 VN À/À mice were immunized with VN(1-66)-Fc [7] and splenocytes were fused to the mouse SP2/0 myeloma cell line by the polyethylene glycol method using standard procedures [50] . Selected hybrids were subcloned by limiting dilution.
Binding assays
Binding assays were performed in black 96-well immunoplates coated with VN (5 lg/ml) in coating buffer (50 mM sodium Ninety-six-well E-plates (Acea Biosciences) were coated with FN (10 lg/ml), VN (5 lg/ml) or recombinant VN variants (5 lg/ml) O/N at 4°C and then blocked with 5% BSA in PBS for 1 h at 37°C. HEK293 cells (15,000 cells/well) in 100 ll serum-free Opti-MEM medium (Life Technologies Corp.) supplemented with 100 U/ml penicillin, 100 U/ml streptomycin and 1 lg/ml tetracycline were seeded in each well. After 15 min of pre-incubation at RT to settle the cells, the plate was transferred to a real-time cell analyser instrument (RTCA, xCELLigence SP, Roche Corp.) located in a humidified cell culture incubator (37°C and 5% CO 2 ). At regular intervals, the impedance (termed cell index, CI) was recorded. Cells were subjected to one or more treatments as reported in the figures and the times at which treatments were performed are indicated in the graphs by vertical lines. Final reagent concentrations were the following: 10 nM sc-uPA, tc-uPA, GFD, PAI-1 and uPA•PAI-1, 30 nM Plg and Pli, 100 nM a2AP and 300 nM aprotinin. To calculate the normalized cell index, all the measured cell indexes were normalized to the cell index recorded in the same well prior to the first treatment.
For experiments conducted using the NCI-60 cell lines, plates were coated with VN and blocked as described above. Cells were seeded at 25,000 cells/well except for HS578T, HOP92, NCI H23, NCI H522, IGROV1, OVCAR3, OVCAR4, OVCAR8, NCI ADR RES, DU145, A498, ACHN, RXF393, SN12C, TK10 and UO31 that were seeded at 12,500 cells/well and 786-0 and CAKI1 that were seeded at 6,250 cells/well. The treatment was performed adding Plg and a2AP (final concentration 30 and 100 nM, respectively), tc-uPA (final concentration 10 nM) or vehicle diluted in Opti-MEM.
Time-lapse imaging
Time-lapse live cell imaging was performed at 37°C, 5% CO 2 with an inverted microscope (IX80, Olympus) equipped with an incubation chamber (OKOlab). Twelve-well plates were coated with VN (5 lg/ml) O/N at 4°C and then blocked with 5% heat-inactivated BSA in PBS for 1 h at 37°C. 293/uPAR cells (250,000 cells/well) were plated in Opti-MEM supplemented with 100 U/ml penicillin, 100 U/ml streptomycin and 1 lg/ml tetracycline. Two hours after seeding, sc-uPA was added to a final concentration of 10 nM and about 1 h later Plg was added to 30 nM. Cells were imaged at regular intervals (2 min) using a 20× objective.
For cell migration experiments, 293/uPAR cells were plated and allowed to adhere as described above. After about 2 h, cells were treated with 10 nM sc-uPA, PAI-1, uPA•PAI-1 or vehicle and imaged every 5 min using a 10× objective. Cell migration was quantified using the "manual tracking" plugin of ImageJ. To obtain a timeresolved quantification of cell speed, we calculated the average migration speed over the 30 min preceding every time point and followed at least 50 individual cells per condition.
Differential interference contrast (DIC) microscopy
Adherent cells were fixed with 4% paraformaldehyde in PBS for 10 min at RT and then washed with PBS. DIC imaging was performed using an inverted microscope Olympus IX81. Cells were viewed through a high-aperture 60× objective (UIS2 60× TIRFM PlanApo N, NA 1.45; Olympus). Images were acquired using Hamamatsu Orca-ER digital camera with the software Metamorph 7.5.6.0. Cell matrix contact area was quantified using ImageJ.
Cell lysis and Western blotting
Cells were lysed directly on the culture dish in Laemmli buffer. Equal volumes were separated by SDS-PAGE and probed as indicated.
Release experiments
For VN fragment release experiments, 12-well plates were coated with VN or VN variants (5 lg/ml) O/N at 4°C and residual binding sites saturated with blocking buffer (5% heat-inactivated BSA in PBS) for 1 h at 37°C. Cells (500,000/well) were seeded in Opti-MEM and allowed to adhere for about 2 h before further treatments. The final concentrations of reagents used in the release experiments were: 10 nM sc-uPA or tc-uPA, 30 nM plasminogen or plasmin, 100 nM a2AP and 300 nM aprotinin. The GFD domain (300 nM) and mAb 8B12 (30 lg/ml) were added to the cells 30 min prior to the addition of proteases. The conditioned media were harvested 2 h after treatment, filtered and added PMSF to 1 mM. For release experiments conducted using NCI-60 cell lines, 50,000 cells/well were seeded in VN-coated 48-well plates in the presence or absence of 30 nM Plg and 100 nM a2AP. Supernatants were collected after 16 h and processed as described above. Quantification of SMBcontaining VN fragments in supernatants was performed by immunoassay. Black 96-well immunoplates were coated with the anti-SMB monoclonal antibody HU3 (0.5 lg/ml) diluted in coating buffer at 4°C O/N. Plates were washed with PBS-T and blocked with The Blocking Solution for ≥ 2 h at RT shaking. After washing with PBS-T, wells were incubated with samples properly diluted in PBS-T. The binding was allowed to occur 1-2 h at RT shaking. Bound VN fragments were detected by sequential incubations with a biotinylated anti-SMB monoclonal antibody HF6 (0.5 lg/ml) and Eu 3+ -labelled streptavidin (1:10,000, Perkin Elmer Corp.) for 1 h at RT shaking. The Eu 3+ -label was detected as described above. Background binding was measured in wells incubated with PBS-T and was subtracted from the total binding. VN(1-61) was used as standard. The standard curve was fitted to the experimental data and the unknown concentrations were interpolated by nonlinear regression using the log[agonist] vs. response-variable slope (four parameter) algorithm and the GraphPad Prism (V6.0b) software.
MALDI-TOF mass spectrometry
For in vitro fragments generation, VN (Promega) or recombinant VN variants were subjected to proteolytic digestion with plasmin or tcuPA for 2 h at 37°C. The reaction was carried out in PBS with a 10:1 (weight/weight, w/w) ratio of VN to protease. Two picomoles of digested VN were deposited onto a MALDI plate and allowed to airdry. Matrix (5 mg/ml a-cyano-hydroxy-cinnamic acid (CHCA) in 50% acetonitrile/0.1% TFA) was spotted directly on top. For the analysis of cell supernatants and human samples, a pull-down assay using HU3-conjugated beads was performed. The ascites were subjected to size-exclusion filtration (30 kDa cut-off) before the immunoprecipitation. Samples were supplemented with Tris-HCl pH 7.5 (final concentration, 50 mM) and PMSF (final concentration, 1 mM), and SMB-containing VN fragments were immunoprecipitated using the conjugated beads. Eluted material was desalted using C8 zip-tip before spotting it on the MALDI plate. Mass spectra were acquired in linear mode on a 4800 MALDI-TOF/TOF mass spectrometer (Applied Biosystems, Foster City, CA) equipped with a 336-nm nitrogen laser. Ions were accelerated with a 20-kV pulse. Spectra were generated in the mass range 2-20 kDa by averaging 40 subspectra for each of 25 randomized positions within the spot (1,000 spectra/spot). Laser intensity was set at 4,000 V to optimize the signal-to-noise ratio and the resolution of mass peaks of the analyte.
Human samples
Fresh ascites were obtained upon informed consent from patients with high-grade serous ovarian carcinoma who underwent paracentesis. Peritoneal fluid was centrifuged at 16.6 g for 5 min and the supernatant was collected and stored at À80°C.
The urine sample was obtained from a healthy volunteer. The sample was snap-frozen and stored at À80°C. Before analysis, the sample was thawed at 37°C and centrifuged.
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